Syneron Announces Availability of elos Plus™ in Canada Following
Health Canada Clearance
YOKNEAM, Israel, Oct. 22, 2012 /PRNewswire/ -- Syneron Medical
Ltd. (NASDAQ: ELOS), www.syneron.com, the leading global aesthetic
device company, announced today Health Canada clearance and the
commercial launch of the elos Plus™ next generation multi-platform
system in Canada. The availability
of elos Plus, which features many of the Syneron's sophisticated
innovations, such as the elos® technology, follows on its recent
launch in the U.S., Europe and
Asia.
(Logo: http://photos.prnewswire.com/prnh/20120528/535447 )
"In today's diverse and competitive aesthetic landscape, owning
a device that is flexible, reliable and offers unique high demand
treatment options is no longer a nice-to-have, it's a must-have,"
said Louis P. Scafuri, Chief
Executive Officer of Syneron. "The new elos Plus was designed with
this dynamic in mind – it is built to out-deliver the competition
in performance, versatility, reliability and scalability to meet
the needs of today's aesthetic practitioners. Our customers in the
U.S., Europe and Asia have been very pleased with all the
features we were able to put inside the elos Plus and we are
excited to now offer the system to our physician partners in
Canada."
"Having owned previous generations of elos™ based systems, I
have been eagerly awaiting the opportunity to add the new elos
Plus™ to my practice," said Sonia
Bansal, M.D., board certified Dermatologist in Danville, California. "I know I can depend on
the elos technology to deliver the utmost in patient satisfaction
and safety, which are the most critical considerations when I
purchase a device. I like how the elos Plus comes equipped
with Syneron's latest signature applications like Sublative™, while
also being a multi-platform device that the Company will
continually build upon, giving me assurance that this platform will
stay current well beyond the purchase date."
For more information about elos Plus™ or any of Syneron's broad
product offering, visit www.syneron.com.
About elos Plus™
The new elos Plus™ leverages the
Company's proprietary elos® technology of optical
energy and bi-polar radiofrequency to provide safe and efficacious
treatments. This state-of-the-art system is customizable or
upgradable utilizing a full range of up to eight in-demand
aesthetic applicators, which also includes the Company's globally
successful Sublative™ and Sublime™ applications. The
intuitive fifteen-inch touch screen offers unparalleled ease-of-use
through it's simple but powerful, guided treatment modes for all
applications. The system is also equipped with the most
popular features from recent Syneron models such as the proprietary
Active Dermal Monitoring™, Intelligent Feedback System™ (IFS) and
Sublative iD™, making elos Plus™ the new workhorse for any
aesthetic practice.
About Syneron Medical Ltd.
Syneron Medical Ltd. – a
company devoted to real technology, real science and real results –
is the leading global aesthetic device company with a comprehensive
product portfolio and a global distribution footprint. The
Company's technology enables physicians to provide advanced
solutions for a broad range of medical-aesthetic applications
including body contouring, hair removal, wrinkle reduction,
rejuvenation of the skin's appearance through the treatment of
superficial benign vascular and pigmented lesions, and the
treatment of acne, leg veins and cellulite. The Company sells
its products under two distinct brands, Syneron and Candela.
The Company's aspiration and commitment to innovation expands
Syneron's offering beyond medical device into the largest in-demand
applications in beauty - skin lightening. Founded in 2000,
the corporate, R&D, and manufacturing headquarters for Syneron
Medical Ltd. are located in Israel. Syneron also has R&D and
manufacturing operations in the US. The company markets and
services and supports its products in 86 countries. It has offices
in North America, France, Germany, Italy, Portugal, Spain, UK, Australia, China, Japan,
and Hong Kong and distributors
worldwide. Additional information can be found at
www.syneron.com.
SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS
Any statements contained in this document regarding future
expectations, beliefs, goals, plans or prospects constitute
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Further, any statements
that are not statements of historical fact (including statements
containing "believes," "anticipates," "plans," "expects," "may,"
"will," "would," "intends," "estimates" and similar expressions)
should also be considered to be forward-looking statements. There
are a number of important factors that could cause actual results
or events to differ materially from those indicated by such
forward-looking statements, including the risk that the businesses
of Syneron and Candela may not be integrated successfully; the risk
that the merger transaction with Candela may involve unexpected
costs or unexpected liabilities; the risk that synergies from the
merger transaction may not be fully realized or may take longer to
realize than expected; the risk that disruptions from the merger
transaction make it more difficult to maintain relationships with
customers, employees, or suppliers; as well as the risks set forth
in Syneron Medical Ltd.'s most recent Annual Report on Form 20-F,
and the other factors described in the filings that Syneron Medical
Ltd. makes with the SEC from time to time. If one or more of these
factors materialize, or if any underlying assumptions prove
incorrect, Syneron Medical Ltd.'s actual results, performance or
achievements may vary materially from any future results,
performance or achievements expressed or implied by these
forward-looking statements.
In addition, the statements in this document reflect the
expectations and beliefs of Syneron Medical Ltd. as of the date of
this document. Syneron Medical Ltd. anticipates that subsequent
events and developments will cause its expectations and beliefs to
change. However, while Syneron Medical Ltd. may elect to update
these forward-looking statements publicly in the future, it
specifically disclaims any obligation to do so. The forward-looking
statements of Syneron Medical Ltd. do not reflect the potential
impact of any future dispositions or strategic transactions that
may be undertaken. These forward-looking statements should not be
relied upon as representing Syneron Medical Ltd.'s views as of any
date after the date of this document.
SOURCE Syneron Medical Ltd.